Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Motti Farbstein"'
Autor:
Avital Bareket-Samish, Michael H. Silverman, Pnina Fishman, Assaf Issachar, Adi Francis, Naama Lev-Cohain, Yael Milgrom, Zivit Harpaz, Muhammad Massarwa, Inbal Itzhak, Wadi Hazou, Marius Braun, Rifaat Safadi, David Hakimian, Motti Farbstein
Publikováno v:
Alimentary Pharmacology & Therapeutics. 54:1405-1415
Background Namodenoson, an A3 adenosine receptor (A3AR) agonist, improved liver function/pathology in non-alcoholic steatohepatitis (NASH) preclinical models. Aim To evaluate the efficacy and safety of namodenoson for the treatment of non-alcoholic f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d5d0f1b1b5d9dc208dd67418135ffc66
https://doi.org/10.1111/apt.16664
https://doi.org/10.1111/apt.16664
Autor:
Rifaat Safadi, Marius Braun, Adi Francis, Yael Milgrom, Muhammad Massarwa, David Hakimian, Wadi Hazou, Assaf Issachar, Zivit Harpaz, Motti Farbstein, Inbal Itzhak, Naama Lev‐Cohain, Avital Bareket‐Samish, Michael H. Silverman, Pnina Fishman
Publikováno v:
Alimentary Pharmacology & Therapeutics. 55:485-486
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45db12684557a144713c3488d8a52f7e
https://doi.org/10.1111/apt.16762
https://doi.org/10.1111/apt.16762
Autor:
William T. Purcell, Ioana Adriana Pusca, Adina Croitoru, Amedeia Lavinir Nita, Muhammad Shaalan Beg, Nebojsa Manojlovic, Michael H. Silverman, Mihai Vasile Marinca, David Bristol, Salomon M. Stemmer, Nelly Cherciu, Inbal Itzhak, Motti Farbstein, Sladjana Natošević, Tudor Ciuleanu, Zivit Harpaz, Doina Ganea, Petar Petrov, Rumyana Nedyalkova Ilieva, Pnina Fishman, Dimitar Kalev
Publikováno v:
Cancers
Volume 13
Issue 2
Cancers, Vol 13, Iss 187, p 187 (2021)
Volume 13
Issue 2
Cancers, Vol 13, Iss 187, p 187 (2021)
Namodenoson, an A3 adenosine-receptor agonist, showed promising results in advanced hepatocellular carcinoma (HCC) and moderate hepatic dysfunction (Child&ndash
Pugh B
CPB) in a phase I/II clinical study. This phase II study investigated na
Pugh B
CPB) in a phase I/II clinical study. This phase II study investigated na
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d30151120833902b9b15bfec9d72247b
https://doi.org/10.3390/cancers13020187
https://doi.org/10.3390/cancers13020187
Autor:
Dimitar Kalev, Pnina Fishman, Petar Petrov, Amedeia Lavinir Nita, Josep M. Llovet, Nebojsa Manojlovic, Rumyana Nedyalkova Ilieva, Doina Elena Ganea, Tudor-Eliade Ciuleanu, Zivit Harpaz, Ioana Adriana Puscas, Adina-Emilia Croitoru, William T. Purcell, Sladjana Natošević, Muhammad Shaalan Beg, Salomon M. Stemmer, Nelly Cherciu, Motti Farbstein, Michael H. Silverman, Mihai Vasile Marinca
Publikováno v:
Journal of Clinical Oncology. 37:2503-2503
2503 Background: There is no established primary treatment for patients with advanced HCC and severe liver dysfunction (Child-Pugh B class; CPB), thus this representing a clear unmet need. Namodenoson, an A3AR agonist, showed promising preliminary re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::342e27d95cbe58b9cad1d7cbb4193681
https://doi.org/10.1200/jco.2019.37.15_suppl.2503
https://doi.org/10.1200/jco.2019.37.15_suppl.2503
Autor:
Noa Chetrit, Pnina Fishman, William D Kerns, Kenneth A. Jacobson, Irina S. Barequet, Motti Farbstein, Sara Bar Yehuda, Hanna J. Garzozi, Gil Sartani, Michael H. Silverman, Gilad Litvin, Erez Bakshi, Oren Tomkins, David Zadok, Ilan Cohn, Zivit Harpaz, Fanni Segev, David Bristol, Sari Fishman, David Varssano, Isaac Avni
Publikováno v:
Ophthalmology. 117:1287-1293
Objective To explore the safety and efficacy of CF101, an A 3 adenosine receptor agonist, in patients with moderate to severe dry eye syndrome. Design Phase 2, multicenter, randomized, double-masked, placebo-controlled, parallel-group study. Particip
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::892ce353f39cb2ceabc184845b3441f6
https://doi.org/10.1016/j.ophtha.2009.11.029
https://doi.org/10.1016/j.ophtha.2009.11.029
Autor:
Emil A Dimitrov, ra Gurman-Balbir, Ameet Pispati, rov Oparanov, Zivit Harpaz, Krasimira M Shimbova, Tatiana Reitblat, Motti Farbstein, David Bristol, Pnina Fishman, BR Bagaria, Michael H Silverman, Girish Bhatia, Alex, Mariyana K Mihaylova, Rumen M Stoilov, Sari Fishman, Shira Cohen, Boytcho Aleks, Rodina N Licheva
Publikováno v:
Immunome Research. 11
Background: CF101, an orally bioavailable A3 adenosine receptor (A3AR) agonist, demonstrated very good safety and anti-inflammatory effect in Phase II clinical studies in patients with rheumatoid arthritis (RA) and psoriasis. A3AR expression level in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::98c13817adb71fcb701947bd8d174b03
https://doi.org/10.4172/1745-7580.1000087
https://doi.org/10.4172/1745-7580.1000087
Autor:
Flora Lubin, Judith Knaani, Motti Farbstein, Hanan Farbstein, Gershom Zajicek, Paul Rozen, Naomi Papo
Publikováno v:
Cancer. 91:833-840
BACKGROUND Calcium supplements to the western-style diet may reduce the risk for colorectal neoplasia. Using rectal epithelial proliferation (REP) measurements as a biomarker of response to intervention, the authors evaluated the effects of 1-year ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24c5d3f0304d148e9342c536a4bf843b
https://doi.org/10.1002/1097-0142(20010215)91:4<833::aid-cncr1071>3.0.co
https://doi.org/10.1002/1097-0142(20010215)91:4<833::aid-cncr1071>3.0.co
Autor:
Isaac, Avni, Hanna J, Garzozi, Irina S, Barequet, Fanni, Segev, David, Varssano, Gil, Sartani, Noa, Chetrit, Erez, Bakshi, David, Zadok, Oren, Tomkins, Gilad, Litvin, Kenneth A, Jacobson, Sari, Fishman, Zivit, Harpaz, Motti, Farbstein, Sara Bar, Yehuda, Michael H, Silverman, William D, Kerns, David R, Bristol, Ilan, Cohn, Pnina, Fishman
To explore the safety and efficacy of CF101, an A(3) adenosine receptor agonist, in patients with moderate to severe dry eye syndrome.Phase 2, multicenter, randomized, double-masked, placebo-controlled, parallel-group study.Sixty-eight patients compl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::9d5658962bd6a6636faf5f51c38010f3
https://europepmc.org/articles/PMC3668568/
https://europepmc.org/articles/PMC3668568/
Autor:
Michael H, Silverman, Vibeke, Strand, Doron, Markovits, Menachem, Nahir, Tatiana, Reitblat, Yair, Molad, Itzhak, Rosner, Michael, Rozenbaum, Reuven, Mader, Muhamad, Adawi, Dan, Caspi, Moshe, Tishler, Pnina, Langevitz, Alan, Rubinow, Joshua, Friedman, Lesly, Green, Amir, Tanay, Avivit, Ochaion, Shira, Cohen, William D, Kerns, Ilan, Cohn, Sari, Fishman-Furman, Motti, Farbstein, Sara Bar, Yehuda, Pnina, Fishman
Publikováno v:
The Journal of rheumatology. 35(1)
Adenosine exerts antiinflammatory effects via activation of the A3 adenosine receptor (A3AR), a Gi protein-associated cell-surface receptor, overexpressed in synovial tissue and peripheral blood mononuclear cells (PBMC) in patients with active rheuma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::83f5262078123f93e43ef08409fe454d
https://pubmed.ncbi.nlm.nih.gov/18050382
https://pubmed.ncbi.nlm.nih.gov/18050382
CF102 for the Treatment of Hepatocellular Carcinoma: A Phase I/II, Open-Label, Dose-Escalation Study
Autor:
Pnina Fishman, Ofer Benjaminov, William D Kerns, Barak Singer, Salomon M. Stemmer, Motti Farbstein, Renana Petoka, Sara Bar Yehuda, Noa Beatrice Ciuraru, Gal Medalia, Sari Fishman, Shira Cohen, Zivit Harpaz, Michael H Silverman
Publikováno v:
The Oncologist. 18:25-26
Background. The A3 adenosine receptor (A3AR) is overexpressed in the tumor and in the peripheral blood mononuclear cells of patients with hepatocellular carcinoma (HCC). The orally active drug candidate CF102, an A3AR agonist, induces apoptosis of HC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7e032a8fc2d066c3849ebdbeb9fea59
https://doi.org/10.1634/theoncologist.2012-0211
https://doi.org/10.1634/theoncologist.2012-0211